Home・Lista de Ações・MediciNova Inc

MediciNova Inc

Fechado

SetorSaúde

1.31 1.55

Comprar Vender

Visão Geral

Variação de preço das ações

24h

Atual

Mín

1.28

Máximo

1.31

Indicadores-chave
By Trading Economics
Rendimento	216K -2.6M
Vendas	35K 187K
EPS	-0.05
Margem de lucro	-1,383.144
Funcionários	6
EBITDA	312K -2.5M

Recomendações
By TipRanks
Recomendações	Comprar
Previsão para 12 meses	+501.5% upside

Dividendos
By Acuity
Próximos Ganhos	12 de ago. de 2026

Estatísticas de Mercado
By TradingEconomics
Capitalização de Mercado	-4.4M 65M
Abertura anterior	-0.24
Fecho anterior	1.31

Sentimento de Notícias

By Acuity

43%

57%

135 / 340 Ranking em Healthcare

MediciNova Inc Gráfico

O desempenho passado não é um indicador confiável de resultados futuros.

Notícias Relacionadas

3 de ago. de 2026, 20:06 UTC

MediciNova Inc. shares are lower, continuing a decline since Friday's close, despite positive movements in major indices like the S&P 500 and Nasdaq 100.

31 de jul. de 2026, 19:56 UTC

Shares of MediciNova Inc. are lower during Friday's session, following a routine decline after an early high. The stock is below its 20-day moving average.

30 de jul. de 2026, 20:51 UTC

MediciNova Inc's shares are lower in after-market hours, reflecting a broader decline in the Biotechnology sub-sector. The asset is near its one-month trading range low.

29 de jul. de 2026, 20:09 UTC

MediciNova Inc shares are lower today, continuing a decline since Tuesday's close, and remain near their opening low amid broader market trends.

28 de jul. de 2026, 18:46 UTC

MediciNova Inc. shares are trading higher today, remaining above Monday's close despite settling back from earlier gains during the session.

27 de jul. de 2026, 19:06 UTC

MediciNova Inc. shares are lower today, reflecting broader market trends amid a significant decline in crude oil prices following eased geopolitical tensions.

24 de jul. de 2026, 23:02 UTC

MediciNova Inc shares increased in after-hours trading, reflecting strong performance since Friday's close, despite mixed market sentiment and no specific company news.

23 de jul. de 2026, 20:06 UTC

MediciNova Inc. shares are lower today, continuing a six-session decline amid routine volatility and remaining significantly below the 20-day moving average.

21 de jul. de 2026, 19:21 UTC

MediciNova Inc. shares are lower amid no specific news, continuing a trend below the 20-day moving average over the past three sessions.

Comparação entre Pares

Variação de preço

MediciNova Inc Previsão

Preço-alvo

By TipRanks

501.5% parte superior

Previsão para 12 meses

Média 8 USD 501.5%

Máximo 10 USD

Mínimo 6 USD

Com base em 2 analistas de Wall Street que oferecem metas de preço de 12 meses para MediciNova Inc - Dist nos últimos 3 meses.

Consenso de Avaliação

By TipRanks

Comprar

2 ratings

Comprar

Manter

Vender

Com base em 2 analistas que deram avaliações de ações para MediciNova Inc - Dist nos últimos 3 meses.

Sentimento

By Acuity

135 / 340 Ranking em Saúde

Informação Financeira

Custos administrativos e de venda

Custos Operacionais

Lucro antes de imposto

Vendas

Custo das vendas

Lucro bruto sobre vendas

Despesa com juros da dívida

EBITDA

Resultado Operacional

Sobre MediciNova Inc

MediciNova, Inc., a biopharmaceutical company, focuses on developing novel and small molecule therapeutics for the treatment of serious diseases with unmet medical needs in the United States. It is developing MN-166 (ibudilast), an oral anti-inflammatory and neuroprotective agent for treating neurological and other disorders, such as primary and secondary progressive multiple sclerosis, amyotrophic lateral sclerosis, chemotherapy-induced peripheral neuropathy, degenerative cervical myelopathy, glioblastoma, and substance dependence and addiction, as well as prevention of acute respiratory distress syndrome, and long COVID. The company's product pipeline also includes MN-221 (bedoradrine), a selective beta-2-adrenergic receptor agonist for the treatment of acute exacerbations of asthma; MN-001 (tipelukast), an orally bioavailable small molecule compound to treat fibrotic and other diseases, including nonalcoholic fatty liver disease and idiopathic pulmonary fibrosis; and MN-029 (denibulin), a tubulin binding agent for treating solid tumor cancers. It has license agreements with Kyorin Pharmaceutical Co., Ltd; Angiogene Pharmaceuticals, Ltd.; and Meiji Seika Kaisha, Ltd. The company was incorporated in 2000 and is headquartered in La Jolla, California.